The aim of the nurse learning modules is to provide a comprehensive learning program to enhance cancer nurses and other health professional’s knowledge of lymphoma.
The Nurse Learning Module will provide an overview of the current management of Hodgkin lymphoma in Australia and internationally. The module will aim to be an interactive webinar that will include case studies to enhance your learning.
The presentation will include how Hodgkin lymphoma is diagnosed, staged, prognostic indicators, current treatment in first line management, the relapsed/refractory setting for patients and emerging therapies.
At the completion of module six participants will have an in-depth knowledge of some of the new therapies available for Hodgkin lymphoma patients. Participants will understand:
- Pathophysiology of Hodgkin lymphoma
- The difference between Hodgkin lymphoma and non-Hodgkin lymphoma
- The different subtypes of Hodgkin lymphoma
- The nurse will develop an understanding of how and why treatment decisions are made for patients
- Have an understanding about the different treatments available for Hodgkin lymphoma patients
- Management of patients in the relapsed or refractory setting
- Nursing implications for caring for the Hodgkin lymphoma patient
Module six presentations
Professor Mark Hertzberg – Director, Department of Haematology, Prince of Wales Hospital, Sydney, NSW
Professor Hertzberg is the Director of the Clinical Haematology Service at the Prince of Wales Hospital and University of NSW in Sydney.
He has a particular interest in clinical trials with expertise in the area of Lymphoma.
He is a Past President of the Haematology Society Australia and New Zealand, and for 7 years was the Chair of the Scientific Advisory Committee of the Australasian Leukaemia Lymphoma Group.
He serves on the Scientific Advisory Committee of the 12th International Hodgkin Lymphoma Symposium.
Post assessment & evaluation survey
To receive you certificate of completion, you need to complete a short assessment that is based on the learning module’s objectives.
At the completion of module six:
Once you have completed the module, you will receive a short assessment and a feedback survey. Once these have been completed, you will be sent via email your certificate of completion for your continuing professional development (CPD) records.
Further reading and resources
Below is a list that includes some of the key publications of the studies that were instrumental in standard practice for Hodgkin lymphoma patients.
Reduced treatment intensity in patients with early stage Hodgkin lymphoma
The New England Journal of Medicine, August 2010
Dose intensification in early unfavourable Hodgkin lymphoma: final analysis of the German Hodgkin study group HD14 trial
Journal of Clinical Oncology, March 2012
Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma
Cochrane Database Syst Rev, May 2017
Escalated-dose BEACOPP in the treatment of patients with advanced – stage Hodgkin lymphoma: 10 years of follow-up of the GHSG HD9 study
Journal of Clinical Oncology, August 2009
Positron emission tomography – guided treatment in early-stage favourable Hodgkin lymphoma: Final results of the international, randomised phase III HD16 trial be German Hodgkin Study Group
Journal of clinical Oncology, September 2019
Omitting radiotherapy in early positron emission tomography – negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the pre-planned interim analysis of the randomised
Journal of Clinical Oncology, March 2014
Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma
New England Journal of Medicine, June 2016